November 24, 2025 Dataset Open Access

Mayer, Leonie

JSON-LD (schema.org) Export

{"@context":"https://schema.org/","@id":"http://doi.org/10.25592/uhhfdm.17971","@type":"Dataset","creator":[{"@id":"https://orcid.org/0000-0001-7102-4358","@type":"Person","affiliation":"Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany","name":"Mayer, Leonie"}],"datePublished":"2025-11-24","description":"<p><strong>Abstract</strong></p>\n\n<p>MVA-MERS-S, a vaccine candidate against Middle East respiratory syndrome (MERS), was recently evaluated in a randomized, placebo-controlled, double-blind phase 1b clinical trial to assess its safety, immunogenicity, and optimal dosing in healthy adults in Hamburg and Rotterdam. A three-dose regimen was safe and elicited robust spike-specific antibody responses. We extended this trial to assess the two-year durability of MERS-CoV-specific antibody and T cell responses in 48 study participants of the Hamburg cohort. Our findings show that immune responses remain detectable for at least 24 months after the third vaccination. &nbsp;Antibodies persisted at levels comparable to the peak response observed after the second vaccination and were able to cross-neutralize MERS-CoV spike mutants. Although the immune correlates of protection against MERS remain unknown, the observed durability of humoral and cellular immune responses supports the potential of MVA-MERS-S as a promising MERS vaccine candidate and highlights the importance of a booster dose in sustaining long-term immunity.</p>","distribution":[{"@type":"DataDownload","contentUrl":"https://www.fdr.uni-hamburg.de/api/files/1add73d7-8c04-425a-8c22-4bfff9b479c4/MVA-MERS-S_DF1 LTFU immunogenicity dataset.xlsx","encodingFormat":"xlsx"}],"identifier":"http://doi.org/10.25592/uhhfdm.17971","keywords":["vaccine","Modified Vaccinia virus Ankara","Middle East respiratory sydrome coronavirus","immunogenicity"],"license":"https://creativecommons.org/licenses/by/4.0/legalcode","name":"Two-year persistence of MERS-CoV-specific antibody and T cell responses  after MVA-MERS-S vaccination in healthy adults","url":"https://www.fdr.uni-hamburg.de/record/17971"}